Kyverna Therapeutics, Inc. – NASDAQ:KYTX

Kyverna Therapeutics stock price today

$3.3
-0.69
-17.29%
Financial Health
0
1
2
3
4
5
6
7
8
9

Kyverna Therapeutics stock price monthly change

-59.24%
month

Kyverna Therapeutics stock price quarterly change

-59.24%
quarter

Kyverna Therapeutics key metrics

Market Cap
167.07M
Enterprise value
N/A
P/E
N/A
EV/Sales
N/A
EV/EBITDA
N/A
Price/Sales
N/A
Price/Book
N/A
PEG ratio
N/A
EPS
N/A
Revenue
N/A
EBITDA
N/A
Income
N/A
Revenue Q/Q
N/A
Revenue Y/Y
N/A
Profit margin
0%
Oper. margin
0%
Gross margin
0%
EBIT margin
0%
EBITDA margin
N/A
Sign up &
create your own Smart Feed

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Sign up for free

Kyverna Therapeutics stock price history

Kyverna Therapeutics stock forecast

Kyverna Therapeutics financial statements

Kyverna Therapeutics, Inc. (NASDAQ:KYTX): Profit margin
2023 0 -60.36M
Kyverna Therapeutics, Inc. (NASDAQ:KYTX): Earnings per share (EPS)
2024-03-26 -3.23 -26.86
2024-05-14 -0.88 -1.12
Kyverna Therapeutics, Inc. (NASDAQ:KYTX): Debt to assets
2023 75195000 26.01M 34.6%
Kyverna Therapeutics, Inc. (NASDAQ:KYTX): Cash Flow
2022 -36.11M -14.09M 11.88M
2023 -52.41M -8.78M 58.11M

Kyverna Therapeutics alternative data

Kyverna Therapeutics, Inc. (NASDAQ:KYTX): Employee count
Apr 2024 96
May 2024 96
Jun 2024 96
Jul 2024 100
Dec 2024 96

Kyverna Therapeutics other data

Kyverna Therapeutics, Inc. (NASDAQ:KYTX): Insider trades (number of shares)
Period Buy Sel
Feb 2024 910000 0
Transaction Date Insider Security Shares Price per share Total value Source
Purchase
GILEAD SCIENCES, INC. 10 percent owner
Common Stock 910,000 $22 $20,020,000
Saturday, 28 December 2024
accesswire.com
accesswire.com
accesswire.com
prnewswire.com
Friday, 27 December 2024
prnewswire.com
accesswire.com
prnewswire.com
accesswire.com
prnewswire.com
accesswire.com
accesswire.com
accesswire.com
accesswire.com
globenewswire.com
accesswire.com
prnewswire.com
accesswire.com
accesswire.com
prnewswire.com
accesswire.com
Thursday, 26 December 2024
accesswire.com
globenewswire.com
accesswire.com
prnewswire.com
accesswire.com
globenewswire.com
accesswire.com
accesswire.com
globenewswire.com
accesswire.com
  • What's the price of Kyverna Therapeutics stock today?

    One share of Kyverna Therapeutics stock can currently be purchased for approximately $3.3.

  • When is Kyverna Therapeutics's next earnings date?

    Unfortunately, Kyverna Therapeutics's (KYTX) next earnings date is currently unknown.

  • Does Kyverna Therapeutics pay dividends?

    No, Kyverna Therapeutics does not pay dividends.

  • How much money does Kyverna Therapeutics make?

    Kyverna Therapeutics has a market capitalization of 167.07M. Kyverna Therapeutics made a loss 60.37M US dollars in net income (profit) last year or -$1.12 on an earnings per share basis.

  • What is Kyverna Therapeutics's stock symbol?

    Kyverna Therapeutics, Inc. is traded on the NASDAQ under the ticker symbol "KYTX".

  • What is Kyverna Therapeutics's primary industry?

    Company operates in the Healthcare sector and Biotechnology industry.

  • How do i buy shares of Kyverna Therapeutics?

    Shares of Kyverna Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

  • How many employees does Kyverna Therapeutics have?

    As Dec 2024, Kyverna Therapeutics employs 96 workers, which is 4% less then previous month.

  • When Kyverna Therapeutics went public?

    Kyverna Therapeutics, Inc. is publicly traded company for just a year since IPO on 9 Feb 2024.

  • What is Kyverna Therapeutics's official website?

    The official website for Kyverna Therapeutics is kyvernatx.com.

  • Where are Kyverna Therapeutics's headquarters?

    Kyverna Therapeutics is headquartered at 5980 Horton Street, Emeryville, CA.

  • How can i contact Kyverna Therapeutics?

    Kyverna Therapeutics's mailing address is 5980 Horton Street, Emeryville, CA and company can be reached via phone at +51 09252492.

Kyverna Therapeutics company profile:

Kyverna Therapeutics, Inc.

kyvernatx.com
Exchange:

NASDAQ

Full time employees:

96

Industry:

Biotechnology

Sector:

Healthcare

Kyverna Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients suffering from autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of patients with lupus nephritis and systemic sclerosis that is in Phase I clinical trial; and for myasthenia gravis and multiple sclerosis that is in Phase II clinical trial. The company is also developing KYV-201, an allogeneic CD19 CAR T-cell product candidate that is in preclinical stage to treat multiple autoimmune diseases. In addition, it is developing product candidates to treat other autoimmune diseases, such as inflammatory bowel disease that includes Crohn's disease and ulcerative colitis. Kyverna Therapeutics, Inc. has a license and collaboration agreement with Intellia Therapeutics, Inc. to research and develop an allogeneic CD19-directed CAR cell therapy product; and with Kite to research and develop programs for the treatment, diagnosis, and prevention of autoimmune, inflammatory, and allogeneic stem cell transplant inflammatory diseases. The company was formerly known as BAIT Therapeutics, Inc. and changed its name to Kyverna Therapeutics, Inc. in October 2019. Kyverna Therapeutics, Inc. was incorporated in 2018 and is headquartered in Emeryville, California.

5980 Horton Street
Emeryville, CA 94608

CIK: 0001994702
ISIN: US5019761049
: